Evidence map›Paper›PMID 28393314›Full record

ArticleMedical oncology (Northwood, London, England)2017

Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.

Maurice Herring, Lynn Huynh, Mei Sheng Duh, Francis Vekeman, Audrey Tiew, Maureen Neary, Emily Bergsland

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maurice HerringUCSF Helen Diller Family Comprehensive Cancer Center, 550 16th St., Box 3211, San Francisco, CA, 94143, USA.
Lynn HuynhAnalysis Group Inc., Boston, MA, USA.
Mei Sheng DuhAnalysis Group Inc., Boston, MA, USA.
Francis VekemanAnalysis Group Inc., Boston, MA, USA.
Audrey TiewAnalysis Group Inc., Boston, MA, USA.
Maureen NearyNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Emily BergslandUCSF Helen Diller Family Comprehensive Cancer Center, 550 16th St., Box 3211, San Francisco, CA, 94143, USA. Emily.Bergsland@ucsf.edu.ORCID http://orcid.org/0000-0001-7754-6552

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic neuroendocrine tumors (pNETs) are rare, slow-growing cancers. Optimal treatment of advanced pNETs is unclear. The aim of this study was to examine treatment patterns and preferences among an academic tertiary medical center and community-based oncology practices. Retrospective chart review was performed for patients with newly diagnosed locally advanced, metastatic, or unresectable pNET diagnosed between January 2010 and December 2013 at an academic tertiary cancer center [University of California, San Francisco (UCSF)] or a large network of community oncology practices [Altos Solutions' OncoEMR database (ALTOS)]. Fifty-four eligible patients (N

Indexed as

Academic Medical CentersAdultAgedAged, 80 and overCancer Care FacilitiesFemaleHumansMaleMiddle AgedMolecular Targeted TherapyNeuroendocrine TumorsPancreatic NeoplasmsPractice Patterns, Physicians'Retrospective StudiesTertiary Care CentersYoung AdultAdvanced pancreatic neuroendocrine tumorsLow-grade neuroendocrine tumorTargeted therapyTreatment pattern

Identifiers

PMID28393314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.